¹Ì±¹ ¸é¿ªÇÐȸ ¿¬·ÊÇÐȸÀÎ À̹³î·ÎÁö ÄÁÆÛ·±½º 2022 ¿¡¼ ¼¼°è °¢ÁöÀÇ ¿¬±¸ÀÚµéÀÇ ¼º°ú¹ßÇ¥¿Í Âü¿©±â¾÷µéÀÇ Àü½Ã°¡ ¿¸®°í ÀÖ´Ù. (»çÁøÁ¦°ø=¼¿¸®¹ö¸®) |
¢ß¼¿¸®¹ö¸®°¡ Áö³ 8ÀÏ ¼¼°è ÃÖ´ë ¸é¿ªÇÐ ÇÐȸÀÎ À̹³î·ÎÁö (IMMUNOLOGY) 2022 (Æ÷Ʋ·£µå, ¿À¸®°Ç ÁÖ, ¹Ì±¹)¿¡ Âü°¡ÇÏ¿©, Áö¿ª»çȸ°¨¿°º´ ¸é¿ªÄ¡·áÁ¦ÀÎ iCP-NIÀÇ ¿¬±¸°³¹ß¼º°ú¸¦ ¹ßÇ¥ÇÏ¿© ¼¼°è Á¤»ó±Þ Çаè·ÎºÎÅÍ ³ôÀº ÇмúÀû °¡Ä¡¸¦ ÀÎÁ¤¹Þ¾Ò´Ù°í 12ÀÏ ¹àÇû´Ù.
¼¿¸®¹ö¸®Ãø »ç¾÷°³¹ß Çٽɰü°èÀÚ´Â, “±âº»ÀûÀ¸·Î ¼¿¸®¹ö¸®ÀÇ Ç÷§Æû±â¼úÀÎ ¾à¸®¹°Áú »ýü³»Àü¼Û±â¼ú TSDT¿¡ ´ëÇÑ °ü½ÉÀÌ ¸Å¿ì ÄÇ´Ù. ³»Àç¸é¿ªÁ¦¾î °¨¿°º´ Ä¡·á½Å¾à iCP-NIÀÇ °³¹ßÁøôµµ ¹× ÀÓ»óÁøÇà»óȲÀ» ÅëÇØ, ½ÇÁ¦·Î TSDT ±â¼úÀÌ »ç¶÷¿¡°Ô Àû¿ëµÈ´Ù´Â Á¡¿¡¼ ¹®ÀÇÇß´ø ¸ðµç À̵éÀÌ ³î¶ó¿öÇß´Ù. ÀÎü »ýü ³» Ä¡·á¹°Áú Àü´ÞÈ¿À²Àº ¸¹Àº Á¦¾à»çµéÀÌ ½Å¾à°³¹ß ½Ã¿¡ °í·ÁÇÏ´Â ÇÙ½É ¿ä°ÇÀÌ´Ù.”, ¶ó°í ¾Ë·È´Ù.
¶ÇÇÑ, “¹ßÇ¥µÈ ¸é¿ªÄ¡·áÁ¦ iCP-NI »Ó¸¸ ¾Æ´Ï¶ó, TSDT Ç÷§Æû±â¼úÀÇ °¡Ä¡ ¿ª½Ã ³ôÀº Æò°¡¸¦ ¹Þ¾Ò´Ù. ¹ßÇ¥¸¦ °æûÇÑ ¹Ì±¹ ÇϹöµå ÀÇ°ú´ëÇÐ ¼Ò¼Ó °ü°èÀÚ´Â, TSDT¸¦ ´Ù¸¥ Ä¡·áÁ¦¿¡ Àû¿ëÇÏ´Â È®Àå °¡´É¼º¿¡ ´ëÇØ ¹®ÀÇÇϸç, “Ç÷§Æû±â¼úÀÇ °¡Ä¡°¡ »ó´çÈ÷ ³ô¾Æ º¸ÀδÙ. ÁÁÀº °á°ú°¡ ÀÖÀ» °ÍÀÌ´Ù (Incredible! Impressive to see its applicability in various types of molecules. I see a lot of potential)” ¶ó°í Æò°¡ÇÏ¿© TSDTÀÇ Çй®Àû/±â¼úÀû °¡Ä¡¸¦ ´Ù½Ã Çѹø È®ÀÎÇÒ ¼ö ÀÖ¾ú´Ù”, ¶ó°í ¼³¸íÇß´Ù.
¶ÇÇÑ, “ÈǸ¢ÇÑ ¿¬±¸°á°úÀÌ´Ù (This is great work: ¹Ì±¹ ±¹¸³º¸°Ç¿ø), ³í¹®¹ßÇ¥°¡ ±â´ëµÈ´Ù (I’m looking forward to its publication: Åػ罺 ÀÇ°ú´ëÇÐ), ÀÓ»ó½ÃÇè±îÁö ÁøÇàµÇ°í ÀÖÀ¸´Ï, ÁÁÀº Ä¡·áÁ¦°¡ µÉ °Í °°´Ù (Since it has already entered into clinical stage, I expect it will become a very promising therapeutic agent: À¯Å¸ ´ëÇÐ) µî ÁÁÀº Æò°¡°¡ ÀÖ¾ú´Ù”, ¶ó°í ÀüÇß´Ù.
À̳¯ TSDT Ç÷§Æû±â¼ú ¹× iCP-NI¿¡ ¹®ÀǸ¦ ÇÑ °úÇÐÀÚµéÀº ¹Ì±¹ ÁÖ¿ä ´ëÇÐµé ¹× ¹Ì±¹ ±¹¸³ ¾Ë·¯Áö ¹× °¨¿°º´ ¿¬±¸¼Ò (NIAID), ¹Ì±¹ ±¹¸³º¸°Ç¿ø (NIH) µîÀÇ ±³¼öÁø ¹× ¿¬±¸ÀÚµéÀÌ ÁÖ¸¦ ÀÌ·ç¾ú´Ù.
¢ß¼¿¸®¹ö¸®Ãø iCP-NI ¿¬±¸°³¹ß Ã¥ÀÓÀÚ´Â, “½Å¾àÀÇ °³¹ß ¹× ¼º°ø°úÁ¤¿¡ ÀÖ¾î ±â¼úÀû °¡Ä¡¸¦ ÀÎÁ¤¹Þ´Â °Í ¸øÁö ¾Ê°Ô, ÇмúÀûÀ¸·Îµµ ¾à¹°ÀÇ ±âÀü°ú ±â´ÉÀÌ Áõ¸íµÇ°í ÀÎÁ¤¹Þ¾Æ¾ß ÇÑ´Ù. Áö³ 2020³â ¼¿¸®¹ö¸®ÀÇ ³úÁúȯġ·á½Å¾àÀÎ iCP-ParkinÀÌ Åé1% °úÇÐÀú³ÎÀÎ »çÀ̾𽺠¾î½ºº¥½Ã½º (Science Advances) ¶ó´Â Á¤»ó±Þ °úÇÐÀú³Î¿¡ ¹ßÇ¥µÇ¾î Àü ¼¼°èÀûÀ¸·Î ÇмúÀû °¡Ä¡¸¦ ÀÎÁ¤¹ÞÀº ÀÌÈÄ, ´õ¿í ¸¹Àº ¹ÙÀÌ¿ÀÁ¦¾à±â¾÷µéÀÌ Á÷Á¢ ¹®ÀǸ¦ ÇÏ°í, ¶Ç »õ·Î¿î ÆÄÆ®³Ê»çµéÀÌ »ý±â´Â °Íó·³, iCP-NIµµ À̹ø ¹Ì±¹ ¸é¿ªÇÐ Çмú´ëȸ À̹³î·ÎÁö 2022¸¦ ½ÃÀÛÀ¸·Î, Çмú³í¹®°ú ƯÇã µî ´Ù¾çÇÑ ¹æ¹ýÀ¸·Î ÇмúÀû, »ç¾÷Àû °¡Ä¡¿¡ ´ëÇØ ÀÎÁ¤¹Þ°í ÀÖ´Ù.” ¶ó°í ¼³¸íÇß´Ù.
À̾î¼, “À¯·´¿¡¼ ÁøÇàµÉ ÀÓ»ó½ÃÇè¿¡ ´ëÇØ, Æú¶õµå Á¤ºÎ±â°ü¿¡¼ °ð ½ÉÀÇ¿¡ ´ëÇÑ °áÁ¤ÀÌ ÀÖÀ» °ÍÀ̶ó´Â Å뺸¸¦ ¹Þ¾Ò´Ù. ½ÂÀÎ ÀÌÈÄÀÇ ½Ç¹«³ª º´»óÈ®º¸, ȯÀÚ¸ðÁý°èȹ µî ½ÇÁ¦ ÀÓ»óÁøÇàÁغñ´Â ´ëºÎºÐ ¼±ÇàµÇ¾îÀÖ°í, ¿Ï·áµÇ¾ú±â ¶§¹®¿¡ °ø½ÄÅ뺸¸¸À» ±â´Ù¸®°í ÀÖ´Ù.” °í ¾ÕÀ¸·Î ÁøÇàµÉ ÀÓ»ó½ÃÇè¿¡ ´ëÇؼµµ ¼³¸íÇÏ¿´´Ù.
¹Ú¿µÀç ±âÀÚ bodo@emoneynews.co.kr
<ÀúÀÛ±ÇÀÚ © À̸Ӵϴº½º, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>